Abstract
In order to improve metabolic stability, a ring structure with a cystine moiety was introduced into TY027 (Tyr- d-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-[3′,5′-(CF 3) 2Bzl]), which is a lead compound of our developing bifunctional peptide possessing opioid agonist and NK1 antagonist activities. TY038 (Tyr- cyclo[ d-Cys-Gly-Phe-Met-Pro- d-Cys]-Trp-NH-[3′,5′-(CF 3) 2Bzl]) was found as a highly selective δ opioid agonist over μ receptor in conventional tissue-based assays, together with an effective NK1 antagonist activity and good metabolic stability with more than 24 h half life in rat plasma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
